Valuation: Polaris Group

Market Cap 10.4B 321M 283M 263M 241M 453M 31.12B 461M 3.14B 1.22B 15.18B 1.21B 1.18B 52.66B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 10.92B 337M 297M 276M 253M 475M 32.67B 484M 3.3B 1.29B 15.93B 1.27B 1.24B 55.28B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
37.54%
Yield 2024 *
-
Yield 2025 -
1 day+0.41%
1 week-5.47%
Current month-10.70%
1 month-7.63%
3 months-31.64%
6 months-61.59%
Current year-61.09%
1 week 11.9
Extreme 11.9
12.5
1 month 11.9
Extreme 11.9
14.35
Current year 11.9
Extreme 11.9
35.95
1 year 11.9
Extreme 11.9
44.55
3 years 11.9
Extreme 11.9
91.1
5 years 11.9
Extreme 11.9
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 2019-02-28
Chief Operating Officer - 2019-01-31
Chief Executive Officer - 2014-04-30
Director TitleAgeSince
Director/Board Member 78 -
Chairman 64 2014-11-23
Director/Board Member 75 2020-02-24
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%-5.47%-67.95%-86.11% 319M
+1.08%-5.74%-4.98%+10.45% 46.06B
+3.13%+5.34%+402.93%+605.08% 38.91B
+2.14%+2.95%+10.83%+65.45% 35.57B
+4.43%-1.51%+6.73%-9.17% 33.13B
+1.23%-2.05%+0.56%+30.76% 26.42B
+0.29%-2.75% - - 16.61B
+14.71%+12.62%+38.50%+146.99% 15.08B
-6.32%-4.86%+4.36%+8.22% 14.08B
+1.82%+0.19%+1.45%-30.74% 12.81B
Average +2.14%-0.47%+43.60%+82.32% 23.9B
Weighted average by Cap. +2.22%-1.28%+75.15%+129.39%

Financials

2024 2025
Net sales 107M 3.3M 2.91M 2.7M 2.48M 4.66M 320M 4.74M 32.29M 12.59M 156M 12.41M 12.14M 542M 40.6M 1.25M 1.1M 1.02M 942K 1.77M 121M 1.8M 12.25M 4.78M 59.23M 4.71M 4.61M 205M
Net income -2.5B -77.29M -67.98M -63.15M -58.08M -109M -7.49B -111M -755M -295M -3.65B -290M -284M -12.67B -3.93B -121M -107M -99.1M -91.14M -171M -11.75B -174M -1.19B -462M -5.73B -455M -445M -19.88B
Net Debt 9.19M 284K 250K 232K 213K 400K 27.49M 407K 2.77M 1.08M 13.41M 1.07M 1.04M 46.52M 517M 15.96M 14.04M 13.04M 12M 22.5M 1.55B 22.9M 156M 60.84M 754M 59.93M 58.64M 2.62B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
26-07-23 NT$12.10 +0.41% 1,135,739
26-07-22 NT$12.05 -2.82% 1,810,418
26-07-21 NT$12.40 +0.81% 671,097
26-07-20 NT$12.30 +0.82% 853,917
26-07-17 NT$12.20 -4.69% 1,333,703
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock